Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

BMRN Biomarin Pharmaceutical Inc

Price (delayed)

$59.12

Market cap

$11.34B

P/E Ratio

21.5

Dividend/share

N/A

EPS

$2.75

Enterprise value

$10.88B

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and ...

Highlights
The net income has surged by 155% year-on-year and by 23% since the previous quarter
Biomarin Pharmaceutical's EPS has surged by 152% YoY and by 22% QoQ

Key stats

What are the main financial stats of BMRN
Market
Shares outstanding
191.78M
Market cap
$11.34B
Enterprise value
$10.88B
Valuations
Price to earnings (P/E)
21.5
Price to book (P/B)
1.95
Price to sales (P/S)
3.83
EV/EBIT
15.86
EV/EBITDA
14
EV/Sales
3.69
Earnings
Revenue
$2.95B
Gross profit
$2.34B
Operating income
$619.65M
Net income
$523.88M
EBIT
$686.29M
EBITDA
$777.43M
Free cash flow
$624.18M
Per share
EPS
$2.75
EPS diluted
$2.7
Free cash flow per share
$3.27
Book value per share
$30.37
Revenue per share
$15.45
TBVPS
$35.1
Balance sheet
Total assets
$7.15B
Total liabilities
$1.35B
Debt
$595.65M
Equity
$5.79B
Working capital
$2.84B
Liquidity
Debt to equity
0.1
Current ratio
5.52
Quick ratio
3.2
Net debt/EBITDA
-0.58
Margins
EBITDA margin
26.4%
Gross margin
79.4%
Net margin
17.8%
Operating margin
21%
Efficiency
Return on assets
7.5%
Return on equity
9.5%
Return on invested capital
12.2%
Return on capital employed
10.5%
Return on sales
23.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BMRN stock price

How has the Biomarin Pharmaceutical stock price performed over time
Intraday
-0.25%
1 week
-3.67%
1 month
-0.08%
1 year
-23.78%
YTD
-10.06%
QTD
-16.37%

Financial performance

How have Biomarin Pharmaceutical's revenue and profit performed over time
Revenue
$2.95B
Gross profit
$2.34B
Operating income
$619.65M
Net income
$523.88M
Gross margin
79.4%
Net margin
17.8%
BMRN financials
The operating income has surged by 193% year-on-year and by 28% since the previous quarter
The net income has surged by 155% year-on-year and by 23% since the previous quarter
Biomarin Pharmaceutical's operating margin has soared by 144% YoY and by 24% from the previous quarter
The net margin has soared by 114% year-on-year and by 19% since the previous quarter

Price vs fundamentals

How does BMRN's price correlate with its fundamentals
Price vs fundamentals
Earnings waterfall
Price vs fair value

Growth

What is Biomarin Pharmaceutical's growth rate over time
BMRN growth chart

Valuation

What is Biomarin Pharmaceutical stock price valuation
P/E
21.5
P/B
1.95
P/S
3.83
EV/EBIT
15.86
EV/EBITDA
14
EV/Sales
3.69
Valuation vs average
Price to earnings (P/E)
Biomarin Pharmaceutical's EPS has surged by 152% YoY and by 22% QoQ
BMRN's P/E is 88% below its 5-year quarterly average of 179.2 and 45% below its last 4 quarters average of 39.3
Price to book (P/B)
The stock's price to book (P/B) is 44% less than its 5-year quarterly average of 3.5 and 22% less than its last 4 quarters average of 2.5
The equity has grown by 14% YoY and by 2.4% from the previous quarter
Price to sales (P/S)
BMRN's price to sales (P/S) is 49% less than its 5-year quarterly average of 7.5 and 23% less than its last 4 quarters average of 5.0
The revenue has grown by 19% YoY and by 3.4% from the previous quarter

Efficiency

How efficient is Biomarin Pharmaceutical business performance
Biomarin Pharmaceutical's ROIC has soared by 171% YoY and by 23% from the previous quarter
BMRN's return on assets has surged by 150% year-on-year and by 23% since the previous quarter
The ROE has soared by 126% YoY and by 19% from the previous quarter
Biomarin Pharmaceutical's return on sales has surged by 126% YoY and by 20% QoQ

Dividends

What is BMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BMRN.

Financial health

How did Biomarin Pharmaceutical financials performed over time
Assets vs liabilities
BMRN's quick ratio has surged by 106% year-on-year and by 8% since the previous quarter
The company's current ratio has surged by 101% YoY and by 3.6% QoQ
Debt vs equity
The debt is 90% smaller than the equity
BMRN's debt to equity has dropped by 52% year-on-year and by 9% since the previous quarter
The debt is down by 45% year-on-year
Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.